Save time and get answers to complex questions with AI chat
Drugpatentwatch trametinib?Is guselkumab off patent in u s?Zemdri plazomicin nce gain exclusivity 2028 patent 2031?The expiration date of the key patent for guselkumab?Alogliptin benz cost?
See the DrugPatentWatch profile for lurbinectedin
What are the guidelines for using lurbinectedin during pregnancy? Lurbinectedin, also known as Xpovio, is a medication used to treat certain types of cancer. As with any medication, its use during pregnancy carries potential risks to both mother and fetus. According to the manufacturer's guidance and the National Toxicology Program (NTP) [1], lurbinectedin has a pregnancy category D, meaning there is positive evidence of human fetal risk. The exact mechanism of how lutbinectedin affects the fetus is not fully understood, but animal studies have shown adverse effects on fetal development. What are the potential risks to the fetus? Studies in rats and rabbits have demonstrated that high doses of lurbinectedin can cause fetal malformations, decreased fetal body weight, and increased rates of fetal death [2]. The exact risk to human fetuses is unknown, and more research is needed to fully understand the potential effects. How should women taking lurbinectedin plan their pregnancies? Due to the potential risks, women of childbearing age taking lurbinectedin should use effective contraception during and for at least 1 month after the final dose of lutbinectedin [3]. If pregnancy does occur, women should discuss the situation with their healthcare provider to weigh the potential risks and benefits of continuing lurbinectedin treatment. What other precautions should women take if they become pregnant while taking lurbinectedin? If a pregnancy occurs while on lurbinectedin, the healthcare provider may recommend stopping the medication to minimize potential harm to the fetus. In some cases, the benefits of continuing lurbinectedin treatment may outweigh the risks, but this decision will be made on a case-by-case basis. It is essential for women of childbearing age to discuss their reproductive options with their healthcare provider before starting lurbinectedin and to carefully weigh the risks and benefits of treatment during pregnancy. Sources: [1] National Toxicology Program. (2016). National Toxicology Program Chemical Repository. Retrieved from https://ntp.niehs.nih.gov/ [2] Eli Lilly and Company. (2020). Xpovio (lurbinectedin) Prescribing Information. [3] Eli Lilly and Company. (2020). Xpovio (lurbinectedin) Patient Information.
Other Questions About Lurbinectedin :